Skip to main content
Clinical Trials/NCT07417826
NCT07417826
Recruiting
Not Applicable

Efficacy of Cognitive-behavioral Therapy (CBT) and Digital Therapy (DT) in the Prevention of Suicide Risk in Patients With Eating Disorders (ED): a Randomized Clinical Trial.

Universitat Autonoma de Barcelona1 site in 1 country150 target enrollmentStarted: October 22, 2025Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
Universitat Autonoma de Barcelona
Enrollment
150
Locations
1
Primary Endpoint
Change from Baseline in Eating Attitudes Test-26 (EAT-26) Score.

Overview

Brief Summary

The purpose of this study is to determine if adding a digital intervention to standard cognitive-behavioral therapy (CBT) is more effective in preventing suicide risk and reducing eating disorder symptoms. Participants will be women between 18 and 65 years old who have recently experienced suicidal ideation or attempts. One group will receive standard group therapy, while the other will receive group therapy plus a mobile application and digital monitoring devices. The goal is to see if digital tools can improve clinical outcomes and safety for patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Gender: Female.
  • Age between 18 and 65 years old.
  • Clinically stable and able to provide written informed consent.
  • Subjects included in the "Suicide Risk Code" (Codi Risc Suïcidi - CRS) program due to recent suicidal ideation or suicide attempts.
  • Patients with a diagnosis of an Eating Disorder (ED).

Exclusion Criteria

  • Presence of intellectual disability or cognitive impairment that prevents understanding the therapy or the study requirements.
  • Diagnosis of Bipolar Disorder or any Psychotic Disorder.
  • Current active substance abuse or dependence.
  • Any medical condition that, in the investigator's opinion, makes participation unsafe or unfeasible.

Arms & Interventions

Cognitive Behavioural Therapy (CBT) + Digital Therapy (DT)

Experimental

Intervention: Cognitive Behavioural Therapy (CBT) + Digital Therapy (DT) (Behavioral)

Cognitive Behavioural Therapy (CBT)

Active Comparator

Intervention: Cognitive Behavioural Therapy (CBT) (Behavioral)

Outcomes

Primary Outcomes

Change from Baseline in Eating Attitudes Test-26 (EAT-26) Score.

Time Frame: Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.

The EAT-26 is a self-report questionnaire used to assess eating disorder risk and symptoms. It consists of 26 items. Total scores range from 0 to 78, where higher scores indicate greater severity of eating disorder symptoms.

Change from Baseline in Bulimic Investigatory Test Edinburgh (BITE) Score.

Time Frame: Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.

The BITE is used to identify individuals with binge-eating and compensatory behaviors. It consists of two subscales: Symptoms (0-30 points) and Severity (0-39 points). We will report the Total Score. Higher scores indicate higher levels of bulimic symptoms.

Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score.

Time Frame: Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.

The C-SSRS Full Scale is a clinical tool used to assess the full spectrum of suicidal ideation and behavior. It consists of two main sections: (1) Suicidal Ideation (A severity scale ranging from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent) and (2) Suicidal Behavior (A scale that tracks the presence of actual, interrupted, or aborted attempts, and preparatory acts rated as Yes/No). For this outcome, we will report the Suicidal Ideation Severity Score. Higher scores indicate a greater severity of suicidal ideation.

Secondary Outcomes

  • Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score.(Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.)
  • Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Score.(Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.)

Investigators

Sponsor
Universitat Autonoma de Barcelona
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Aleix Jorba Chacón

Clinical psychologist

Universitat Autonoma de Barcelona

Study Sites (1)

Loading locations...

Similar Trials